Myriad Genetics (NASDAQ:MYGN) Updates FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.070-0.110 for the period, compared to the consensus estimate of 0.090. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $883.1 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.

Myriad Genetics Trading Down 3.9 %

NASDAQ:MYGN opened at $13.15 on Thursday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average of $14.89 and a 200 day moving average of $22.04. The firm has a market capitalization of $1.20 billion, a P/E ratio of -10.12 and a beta of 1.89. Myriad Genetics has a 52 week low of $12.81 and a 52 week high of $29.30.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. StockNews.com upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Bank of America cut their price target on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a report on Friday, December 13th. Piper Sandler decreased their price objective on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, November 11th. Leerink Partners cut Myriad Genetics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Finally, Leerink Partnrs lowered Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Myriad Genetics has a consensus rating of “Hold” and an average price target of $24.27.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.